Targeting the shared beta-chain of the IL-3, IL-5 and GM-CSF receptors as therapy for allergic inflammation

这项研究旨在为过敏性疾病如哮喘和过敏性鼻炎开发新的治疗方法，这些疾病在澳大利亚仍然是重大的公共卫生问题。我们将开发针对共同受体途径的疗法，有可能完全抑制急性和慢性疾病，同时保持单一分子靶点。我们将使用表达该受体的人类形式的新型小鼠品系进行用于治疗过敏性疾病的抗体的临床前测试

This research aims to develop new treatments for allergic diseases such as asthma and allergic rhinitis, which remain significant public health problems in Australia. We will develop therapies targeting a common receptor pathway with the potential to completely suppress acute and chronic disease whilst maintaining a single molecular target. We will perform preclinical testing of antibodies for treatment of allergic disorders using a novel mouse strain expressing the human form of this receptor